A RANDOMİZED CONTROLLED TRİAL COMPARİNG THE EFFECTİVENESS OF MYOFASCİAL RELEASE, LOW-LEVEL LASER THERAPY, AND PELOİD THERAPY İN PATİENTS DİAGNOSED WİTH MİLD TO MODERATE CARPAL TUNNEL SYNDROME
This randomized controlled trial aims to compare the effectiveness of low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy in patients diagnosed with mild to moderate carpal tunnel syndrome (CTS). A total of 84 eligible participants aged 18-65 years will be randomly assigned to one of three treatment groups. Group 1 (LLLT): Patients will receive low-level laser therapy 5 days a week for 3 weeks (total 15 sessions). Group 2 (Myofascial Release): Patients will receive manual myofascial release therapy 3 days a week for 5 weeks. Group 3 (Peloid Therapy): Patients will receive peloid (mud) therapy at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions). Clinical evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. The primary outcome measures are the Boston Carpal Tunnel Questionnaire (BCTSQ) and Jamar dynamometer grip strength. Secondary outcome measures include ultrasonographic median nerve cross-sectional area (CSA) and electrophysiological nerve conduction studies (EMG).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Background and Rationale: Carpal Tunnel Syndrome (CTS) is the most common peripheral nerve entrapment syndrome, resulting from the compression of the median nerve at the wrist. Conservative treatment options play a primary role in the management of mild to moderate CTS, aiming to reduce pain, alleviate symptoms, and improve functional status without immediate surgical intervention. This single-center, randomized controlled trial aims to compare the clinical and objective effectiveness of three distinct conservative modalities-low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy-routinely used in clinical practice. Study Design and Participants: A total of 84 male and female patients aged 18-65 years diagnosed with mild to moderate CTS at the Department of Physical Medicine and Rehabilitation, SBÜ Konya Beyhekim Training and Research Hospital, will be enrolled. Participants will be randomized into three intervention groups using a computer-generated randomization scheme. Intervention Groups:• Group 1 (Low-Level Laser Therapy - LLLT): Patients will receive LLLT administered by an experienced technician 5 days a week for 3 weeks (15 sessions in total). Treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light at an 860 nm wavelength, 1 kHz frequency, and 100 mW power output. The dosage will be 3.6 J/cm2, applied perpendicular to the skin over an area of approximately 15-20 cm2 for 40 seconds, with a total session duration of 120 seconds. • Group 2 (Myofascial Release - MFR): Patients will receive manual myofascial release therapy performed by an experienced physician 3 days a week for 5 weeks (15-30 minutes per session). The intervention will involve identifying tight muscle bands and trigger points in the wrist and forearm, applying direct pressure, gentle stretching, and implementing specific nerve and tendon gliding exercises. • Group 3 (Peloid Therapy): Patients will receive medical peloid therapy (sourced from Köyceğiz, Muğla, rich in organic/inorganic substances and humic acid) applied 5 days a week for 3 weeks (15 sessions in total). A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped with a plastic bag and towel for 20 minutes, followed by gentle cleansing with warm water. Outcome Measures and Evaluation Schedule: Evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. • Primary Outcome Measures: Symptom severity and functional status assessed via the Boston Carpal Tunnel Questionnaire (BCTSQ), and maximum grip strength measured objectively using a Jamar dynamometer. • Secondary Outcome Measures: Ultrasonographic assessment of the median nerve cross-sectional area (CSA) at the wrist level and electrophysiological nerve conduction studies (EMG) performed at the 12-week control.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: RAİKAN BÜYÜKAVCI, MD, Prof.
- Phone Number: 4042 +90-0332-224-30-00
- Email: rsoydemir@yahoo.com
Study Locations
-
-
-
Konya, Turkey (Türkiye), 42000
- Recruiting
- University of Health Sciences, Konya Beyhekim Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 65 years.
- Diagnosis of mild or moderate Carpal Tunnel Syndrome (CTS) confirmed by electrophysiological tests (EMG).
- Symptoms persisting for at least 3 months.
- No prior history of surgical treatment for carpal tunnel syndrome.
Exclusion Criteria:
- Severe carpal tunnel syndrome detected by electrophysiological tests.
- History of severe trauma, fracture, or surgery in the same extremity within the last 6 months.
- Having received physical therapy (TENS, laser, exercise, etc.) or injection therapy for CTS within the last 3 months.
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Low-Level Laser Therapy (LLLT) Group
Patients in this group will receive low-level laser therapy (LLLT) administered 5 days a week for 3 weeks, totaling 15 sessions. The treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light. |
Low-level laser therapy administered 5 days a week for 3 weeks (total 15 sessions) using a GaAlAs diode laser. |
|
Active Comparator: Myofascial Release (MFR) Group
Patients in this group will receive manual myofascial release (MFR) therapy performed 3 days a week for 5 weeks. The intervention involves identifying tight muscle bands and trigger points in the wrist and forearm, applying direct manual pressure, gentle stretching, and specific nerve and tendon gliding exercises. |
Manual myofascial release therapy performed 3 days a week for 5 weeks, including trigger point release and neural/tendon gliding exercises. |
|
Active Comparator: Peloid Therapy Group
Patients in this group will receive medical peloid (mud) therapy applied 5 days a week for 3 weeks, totaling 15 sessions. A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped for 20 minutes, and then gently cleansed with warm water. |
Medical peloid therapy applied at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions). |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Boston Carpal Tunnel Questionnaire (BCTSQ) Score
Time Frame: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.
|
Assessment of symptom severity and functional status using the Boston Carpal Tunnel Questionnaire (BCTSQ), which consists of a Symptom Severity Scale (11 items) and a Functional Status Scale (8 items), scored from 1 (best) to 5 (worst). |
Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.
|
|
Maximum Grip Strength
Time Frame: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.
|
Objective measurement of maximum hand grip strength evaluated using a Jamar dynamometer (recorded in kilograms or pounds). |
Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ultrasonographic Median Nerve Cross-Sectional Area (CSA)
Time Frame: Baseline and at the 12-week follow-up.
|
Assessment of the median nerve cross-sectional area (CSA) at the wrist level using high-resolution ultrasonography to evaluate structural changes and reduction in nerve swelling. |
Baseline and at the 12-week follow-up.
|
|
Electrophysiological Nerve Conduction Parameters (SNCV, SNAP, CMAP, DML)
Time Frame: Baseline and at the 12-week follow-up.
|
Evaluation of median nerve conduction characteristics, including sensory nerve conduction velocity (SNCV), sensory nerve action potential (SNAP) amplitude, compound muscle action potential (CMAP) amplitude, and distal motor latency (DML). |
Baseline and at the 12-week follow-up.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: ERDİ İNCİGÜZ, M.D., University of Health Sciences, Konya Beyhekim Training and Research Hospital
- Study Chair: RAİKAN BÜYÜKAVCI, MD, Prof., University of Health Sciences, Konya Beyhekim Training and Research Hospital
Publications and helpful links
General Publications
- Padua L, Coraci D, Erra C, Pazzaglia C, Paolasso I, Loreti C, Caliandro P, Hobson-Webb LD. Carpal tunnel syndrome: clinical features, diagnosis, and management. Lancet Neurol. 2016 Nov;15(12):1273-1284. doi: 10.1016/S1474-4422(16)30231-9. Epub 2016 Oct 11.
- Wipperman J, Goerl K. Carpal Tunnel Syndrome: Diagnosis and Management. Am Fam Physician. 2016 Dec 15;94(12):993-999.
- Jimenez-Del-Barrio S, Cadellans-Arroniz A, Ceballos-Laita L, Estebanez-de-Miguel E, Lopez-de-Celis C, Bueno-Gracia E, Perez-Bellmunt A. The effectiveness of manual therapy on pain, physical function, and nerve conduction studies in carpal tunnel syndrome patients: a systematic review and meta-analysis. Int Orthop. 2022 Feb;46(2):301-312. doi: 10.1007/s00264-021-05272-2. Epub 2021 Dec 3.
- Roll SC, Takata SC, Yao B, Kysh L, Mack WJ. Sonographic reference values for median nerve cross-sectional area: A meta-analysis of data from healthy individuals. J Diagn Med Sonogr. 2023 Sep;39(5):492-506. doi: 10.1177/87564793231176009. Epub 2023 Jun 6.
- Sezgin M, Incel NA, Serhan S, Camdeviren H, As I, Erdogan C. Assessment of symptom severity and functional status in patients with carpal tunnel syndrome: reliability and functionality of the Turkish version of the Boston Questionnaire. Disabil Rehabil. 2006 Oct 30;28(20):1281-5. doi: 10.1080/09638280600621469.
- Savas S, Kilavuz A, Kayhan Kocak FO, Cavdar S. Comparison of Grip Strength Measurements by Widely Used Three Dynamometers in Outpatients Aged 60 Years and Over. J Clin Med. 2023 Jun 25;12(13):4260. doi: 10.3390/jcm12134260.
- Thomson JG. Diagnosis and treatment of carpal tunnel syndrome. Lancet Neurol. 2017 Apr;16(4):263. doi: 10.1016/S1474-4422(17)30059-5. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Wounds and Injuries
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Median Neuropathy
- Mononeuropathies
- Nerve Compression Syndromes
- Cumulative Trauma Disorders
- Sprains and Strains
- Carpal Tunnel Syndrome
- Therapeutics
- Complementary Therapies
- Physical Therapy Modalities
- Rehabilitation
- Laser Therapy
- Phototherapy
- Therapy, Soft Tissue
- Musculoskeletal Manipulations
- Massage
- Balneology
- Low-Level Light Therapy
- Myofascial Release Therapy
- Mud Therapy
Other Study ID Numbers
Other Study ID Numbers
- KonyaBeyhekimTRH/01-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Prerequisites / What data will be shared:De-identified individual participant data (including demographic data, baseline and follow-up Boston Carpal Tunnel Questionnaire scores, Jamar grip strength measurements, ultrasonographic median nerve cross-sectional area [CSA] values, and electrophysiological nerve conduction parameters) underlying the results reported in the future publication will be shared.Supporting Documents:Study Protocol and Informed Consent Form will also be available upon request.Time Frame:Available beginning 3 months and ending 5 years following article publication.Access Criteria:Requests should be directed to the corresponding author via email. Data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, provided that a signed data access agreement is established.
IPD Sharing Time Frame
Available beginning 3 months and ending 5 years following article publication.
IPD Sharing Access Criteria
Requests should be directed to the corresponding author via email. De-identified individual participant data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, upon the establishment of a signed data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.